---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-088715"
form_type: "8-K"
ticker: null
cik: "0001673772"
company_name: "RAPT Therapeutics, Inc."
filed_at: "2025-06-23T23:59:59+00:00"
generated_at: "2026-05-18T23:50:55.046269+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# RAPT Therapeutics appoints Scott Braunstein and Ashley Dombkowski to board, expands to 7 directors

## Summary
- Board expanded from 5 to 7; Drs. Braunstein and Dombkowski appointed as Class III directors with terms expiring at 2028 annual meeting.
- Braunstein brings 30+ years pharma experience; currently operating partner at Aisling Capital, former CEO of Marinus Pharmaceuticals.
- Dombkowski brings over 20 years operating & venture experience; current CEO of Cellics Therapeutics, former CEO of Alladapt Immunotherapeutics.
- Each new director receives initial option grant of 25,000 shares and enters indemnification agreement; compensation policy amended.
- Braunstein appointed to Audit Committee; Dombkowski to Nominating and Corporate Governance Committee.

## SEC filing metadata
- accession: 0000950170-25-088715
- form_type: 8-K
- cik: 0001673772
- company_name: RAPT Therapeutics, Inc.
- filed_at: 2025-06-23T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1673772/000095017025088715/0000950170-25-088715-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1673772/000095017025088715/rapt-20250623.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-088715
- JSON: https://secwatch.observer/filing/0000950170-25-088715.json
- Plain text: https://secwatch.observer/filing/0000950170-25-088715.txt

## Key facts
- Executive change
  Scott Braunstein, M.D. was appointed as Class III director at RAPT Therapeutics, Inc..
  - Action: appointed
  - Role: Class III director
  source text: On June 21, 2025, the Board of Directors (the “Board”) of RAPT Therapeutics, Inc. (the “Company”) increased the size of the Board from five to seven directors and, upon the recommendation of its Nominating and Corporate Governance Committee, appointed Scott Braunstein, M.D. and Ashley Dombkowski, Ph.D., as Class III directors of the Company, with terms expiring at the Company’s 2028 annual meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1673772/000095017025088715/0000950170-25-088715-index.htm
- Executive change
  Ashley Dombkowski, Ph.D. was appointed as Class III director at RAPT Therapeutics, Inc..
  - Action: appointed
  - Role: Class III director
  source text: On June 21, 2025, the Board of Directors (the “Board”) of RAPT Therapeutics, Inc. (the “Company”) increased the size of the Board from five to seven directors and, upon the recommendation of its Nominating and Corporate Governance Committee, appointed Scott Braunstein, M.D. and Ashley Dombkowski, Ph.D., as Class III directors of the Company, with terms expiring at the Company’s 2028 annual meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1673772/000095017025088715/0000950170-25-088715-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.